Twist Bioscience (TWST) Common Equity (2017 - 2026)

Twist Bioscience (TWST) has reported Common Equity for 10 consecutive years, with $445.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 6.79% year-over-year to $445.7 million in Q2 2026; TTM through Jun 2026 was $445.7 million, a 6.79% decrease from a year earlier, with the FY2025 full-year figure at $473.0 million, changed 0.06% from the prior year.
• Common Equity was $445.7 million for Q2 2026 at Twist Bioscience, down from $455.1 million in the prior quarter.
• Over five years, Common Equity peaked at $863.4 million in Q1 2022 and troughed at $440.1 million in Q1 2025.
• A 5-year average of $584.6 million and a median of $525.6 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 40.57% in 2022 and decreased 25.31% in 2024, its largest moves.
• Over 5 years, Common Equity stood at $746.3 million in 2022, then declined by 20.94% to $590.0 million in 2023, then dropped by 22.73% to $455.9 million in 2024, then gained by 0.03% to $456.1 million in 2025, then fell by 2.27% to $445.7 million in 2026.
• The last three Common Equity figures came in at $445.7 million (Q2 2026), $455.1 million (Q1 2026), and $456.1 million (Q4 2025), per Business Quant data.